Collegium Pharmaceutical, Inc.
COLL
$34.87
-$0.82-2.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 14.50M | 16.96M | 31.51M | 11.98M | 2.42M |
| Total Depreciation and Amortization | 55.94M | 56.40M | 56.51M | 56.61M | 56.56M |
| Total Amortization of Deferred Charges | 819.00K | 1.28M | 1.34M | 1.36M | 1.37M |
| Total Other Non-Cash Items | 9.71M | 14.58M | -2.42M | 8.36M | 10.75M |
| Change in Net Operating Assets | -23.85M | 33.83M | -8.50M | -5.86M | -15.70M |
| Cash from Operations | 57.11M | 123.05M | 78.44M | 72.44M | 55.40M |
| Capital Expenditure | -270.00K | -689.00K | -188.00K | -65.00K | -798.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.90M | -19.38M | -30.68M | -2.85M | -8.88M |
| Cash from Investing | 1.63M | -20.07M | -30.87M | -2.92M | -9.68M |
| Total Debt Issued | -- | 565.18M | -- | -- | -- |
| Total Debt Repaid | -7.25M | -587.12M | -16.15M | -16.15M | -16.15M |
| Issuance of Common Stock | 1.34M | 985.00K | 2.29M | 308.00K | 2.06M |
| Repurchase of Common Stock | -15.43M | -861.00K | -964.00K | -25.53M | -10.59M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -7.00M | -555.00K |
| Cash from Financing | -21.34M | -21.82M | -14.82M | -48.37M | -25.24M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 37.40M | 81.16M | 32.75M | 21.15M | 20.48M |